PeptiDream Announces License of PeptiDream's Peptide Discovery Platform System (PDPS) Technology to Bristol-Myers Squibb and

  PeptiDream Announces License of PeptiDream's Peptide Discovery Platform
  System (PDPS) Technology to Bristol-Myers Squibb and Extension of the
  Macrocyclic Peptide Drug Discovery Alliance Between the Companies

Business Wire

TOKYO -- September 17, 2013

PeptiDream Inc, a public Tokyo-based biopharmaceutical company
(“PeptiDream”)(TOKYO:4587) announced today that it has entered into a
Technology License Agreement with US-based Bristol-Myers Squibb (NYSE:BMY) to
nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform
System (PDPS) technology. Under the terms of the Technology License Agreement,
PeptiDream will receive upfront and annual technology access payments, and
will be eligible to receive development milestones and royalties on future
sales of products that arise from use of the PDPS technology.

In addition to the technology license agreement, PeptiDream announced today
the 2^nd extension of its macrocyclic peptide drug discovery alliance with
Bristol-Myers Squibb, originally intiated October 15, 2010, and extended
October 15, 2012. Under the terms of the new 2 year extension (through October
2015), PeptiDream will continue to identify macrocyclic peptides as potential
drug candidates for Bristol-Myers Squibb’s targets by using PDPS for
translational synthesis, selection, and screening of nonstandard macrocyclic
peptides. Bristol-Myers Squibb will own all rights to lead peptides and will
be responsible for all subsequent research and development as pharmaceutical
candidates. PeptiDream will continue to receive research funding and is
eligible to receive milestone payments upon the successful achievement of
certain development milestones and royalties on future sales of products that
arise from the collaboration.

Kiichi Kubota, CEO of PeptiDream, stated “the PDPS technology license was
based on the successes achieved during the first 3 years of our discovery
collaboration with Bristol-Myers Squibb, and further validates PeptiDream’s
platform as the leading peptide discovery platform.” In addition, the
extension of PeptiDream’s discovery partnership with Bristol-Myers Squibb for
an additional 2 years, “will allow both companies to continue our mutual
efforts to drive a number of exciting macrocyclic peptide programs into the
clinic in both the US and Japan.” Kiichi also stated that “the upfront
payment, annual technology access payments, and the continued R&D funding
payable by Bristol-Myers Squibb to PeptiDream will significantly contribute to
PeptiDream’s revenue, starting from this fiscal year, while potential
development milestone payments and product sales royalties offer the
possibility of revenues far into the future.”

Contact:

Enquiries:
PeptiDream Inc.
Patrick C Reid, +81-3-3468-9022 (Tokyo)
p-reid@peptidream.com
 
Press spacebar to pause and continue. Press esc to stop.